The Raynaud’s Condition Score (RCS) is a clinically validated scale used to determine the difficulty that patients experience with Raynaud’s phenomenon, and is closely associated with the measures of disability and overall impact and activity of the disease.

- A reliable measure among patients with scleroderma and Raynaud’s phenomenon
- Clinical trials support the construct, content, criterion, and discriminant validities of the RCS for Raynaud’s phenomenon
- Demonstrates a substantial association between the RCS value and patients’ and physicians’ assessments of Raynaud’s phenomenon activity
- The RCS integrates the impact and activity of Raynaud’s phenomenon and is an excellent summary measure

References:
3. Data on file, MediQuest Therapeutics, Inc.
Raynaud’s Condition Score

A PATIENT-REPORTED MEASURE OF DISEASE SEVERITY

The Raynaud’s Condition Score (RCS) is a scale that expresses the level of difficulty patients experience with Raynaud’s. Patients consider the frequency, duration, and severity of attacks to arrive at a single score expressed on a scale of zero to ten.

Consider how many attacks you had and how long they lasted. Consider how much pain, numbness, or other symptoms the Raynaud’s caused in your fingers (including painful sores) and how much the Raynaud’s ALONE affected the use of your hands today.

– Instructions to clinical study patients

A RELIABLE, CLINICALLY VALIDATED MEASURE¹,²

• The Raynaud’s Condition Score is a reliable measure among patients with scleroderma and Raynaud’s phenomenon

• The RCS integrates the impact and activity of Raynaud’s phenomenon and is an excellent summary measure

• The frequency and duration of Raynaud’s phenomenon attacks are conventional disease measurements, which correlate well with the RCS
  – Frequency and duration of the attacks alone do not take into account other aspects of the disease and do not correlate well with overall disability

• That RCS values differ between patients with and without digital ulcers exemplifies the additional dimension of disease captured by the RCS

• The RCS is sensitive to changes in patients’ disease severity

• The RCS has been used in clinical trials to determine the effectiveness of various treatments²

• Patients’ RCS summary assessments of frequency, duration, severity, and impact of Raynaud’s phenomenon attacks are strongly associated with measures of disability and overall impact and activity of the disease

Raynaud’s Phenomenon

“Raynaud’s phenomenon is present in more than 95% of patients with systemic scleroderma, and typically precedes the onset of systemic disease by several years.”¹

Raynaud’s phenomenon affects approximately 3% of the American population, or some 9 to 11 million individuals. A significant majority of patients are women whose first encounter with Raynaud’s occurred during their 30s and 40s, although onset can occur as early as 15 years of age.³

Raynaud’s can occur with or without scleroderma, lupus, rheumatoid arthritis, or other rheumatologic diseases. However, when present, the pain, numbness, and tingling associated with Raynaud’s can be more severe or even debilitating. Permanent tissue damage in the form of skin ulcers or gangrene also may result. If your patients are experiencing these or similar symptoms, talk to them about Raynaud’s phenomenon.

RAYNAUD’S CONDITION SCORE AS EVALUATION TOOL

The accurate and precise measurement of Raynaud’s phenomenon activity and the functional status of Raynaud’s patients is essential to understanding which treatments are most appropriate. The Raynaud’s Condition Score has proved a reliable tool in determining patients’ sensitivity to change, and is an effective means by which to validate the various outcome measures across multiple clinical trials.¹,²,⁴

Used as a standalone evaluation tool or in association with a variety of existing hard data measurement tests, the RCS is an important instrument for the study of existing and future therapies for Raynaud’s phenomenon.

MEDIQUEST AND RAYNAUD’S PHENOMENON

MediQuest Therapeutics is a specialty pharmaceutical company developing first- and best-in-class topical therapies to treat patients experiencing inflammatory and infectious diseases. MediQuest is committed to satisfying unmet needs in these areas through innovative therapies and drug delivery—beginning with a pending therapy dedicated to treating patients suffering from Raynaud’s phenomenon.